Keywords: drug, ineffective, gi, cancers, johnson, revealed, its

J&J drug ineffective in GI cancers

Article | 27 May 2002

Print This

Johnson & Johnson has revealed that its oncology drug R115777 failed todemonstrate a significant improvement in survival in a Phase III ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in